📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Gujarat Apollo Targets ₹300 Cr Revenue in 3 Years via Dual-Engine Growth Strategy
Gujarat Apollo Industries has unveiled a strategic roadmap to achieve over ₹300 crore in combined revenue within the next three fiscal cycles. The company is leveraging its legacy in road-construction and mining equipment (target ₹210 Cr) while diversifying into the high-demand agriculture sector (target ₹90 Cr). A committed capex of ₹26 crore, funded through equity warrant conversion, will be used for facility modernization and capacity expansion by June 2026. This strategy marks the company's return to the road-construction segment following the end of a non-compete agreement.
Key Highlights
Targeting ₹300 Cr+ combined revenue in 3 years and ₹500 Cr+ by 2031
Allocating ₹26 Cr for modernization and expansion, funded via preferential warrant conversion
Expanding into Agri-equipment with a ₹90 Cr revenue target through subsidiaries like Fieldtrack and Ganesh Agro
Restarting the Road-construction equipment business and developing new Pick & Carry cranes
Acquiring a 50% stake in Ganesh Agro Equipment to bolster the agriculture portfolio
💼 Action for Investors
Investors should monitor the execution of the ₹26 crore capex and the successful re-entry into the road-construction market. The diversification into agri-equipment offers a balanced risk profile, making the company a potential turnaround play in the industrial sector.
Apollo Pipes Appoints Parag Dadeech as Chief Operating Officer
Apollo Pipes has appointed Mr. Parag Dadeech as the Chief Operating Officer (COO) effective March 02, 2026. Mr. Dadeech is a seasoned professional with over 28 years of global experience in the manufacturing sector, specializing in operations and supply chain management. His academic credentials include a Master's in Chemical Engineering from the University of Tennessee and a certification from IIM Kolkata. This appointment is expected to strengthen the company's operational efficiency and strategic manufacturing initiatives.
Key Highlights
Appointment of Mr. Parag Dadeech as COO and Senior Management Personnel effective March 02, 2026
Brings over 28 years of global experience in manufacturing, operations, and international business
Holds a Master's degree in Chemical Engineering from the University of Tennessee and is a Lean Six Sigma Master Black Belt
Expertise includes Business Excellence, Global Supply Chain, and Capital Projects management
💼 Action for Investors
Investors should view this as a positive step toward professionalizing management and improving operational scale. Monitor future quarterly results for improvements in manufacturing margins and supply chain efficiencies under the new leadership.
Apollo Pipes Increases Stake in Subsidiary Kisan Mouldings to 61.94% for Rs 9.8 Cr
Apollo Pipes Limited has increased its ownership in its subsidiary, Kisan Mouldings Limited (KML), by acquiring an additional 3.34% stake through a secondary purchase. The transaction, valued at approximately Rs 9.8 Crores, raises Apollo's total holding from 58.60% to 61.94%. KML is a key player in the PVC pipes and fittings industry, reporting a turnover of Rs 273.35 Crores for FY25. This strategic investment demonstrates Apollo Pipes' commitment to consolidating its position within its core business segment.
Key Highlights
Acquired an additional 3.34% equity stake in Kisan Mouldings Limited (KML) via secondary purchase
Total shareholding in the subsidiary increased from 58.60% to 61.94%
The acquisition was completed for a cash consideration of approximately Rs 9.8 Crores
Target entity KML reported a steady turnover of Rs 273.35 Crores in FY 2024-25
The move is classified as a strategic investment in the PVC Pipes & Fittings industry
💼 Action for Investors
Investors should view this as a positive move to consolidate control over a significant subsidiary. Monitor how this increased ownership impacts consolidated earnings and operational synergies in the coming quarters.
Promoter Group Entity Acquires 1.18% Stake in Apollo Pipes for ₹76.65 Crore
S Gupta Holding Private Limited, a member of the promoter group, has acquired 5,25,000 equity shares of Apollo Pipes through a market purchase. The transaction, valued at approximately ₹76.65 crore, represents a 1.18% stake in the company. This significant acquisition by the promoter group is a strong signal of confidence in the company's valuation and future prospects. The trade was executed on February 13, 2026, and reported to the exchanges on February 19.
Key Highlights
Acquisition of 5,25,000 equity shares by promoter group entity S Gupta Holding Private Limited.
Total transaction value of ₹76.65 crore executed via market purchase.
The purchase represents a 1.18% stake in the company, increasing the entity's holding from nil to 1.18%.
Transaction executed at an approximate price of ₹1,460 per share on February 13, 2026.
💼 Action for Investors
Promoter buying at market prices is typically a bullish sign for long-term investors. Consider this a positive reinforcement of the company's fundamentals and monitor for further insider activity.
Gujarat Apollo Q3 Consolidated PAT Plummets 90% YoY to ₹22 Lakhs; Equity Capital Increases
Gujarat Apollo Industries reported a significant decline in consolidated profitability for the quarter ended December 31, 2025, with PAT dropping to ₹22.04 lakhs from ₹228.75 lakhs in the previous year. While consolidated revenue saw a modest 9% growth to ₹1,187.45 lakhs, standalone revenue fell by 33.8% to ₹920.99 lakhs. The company expanded its equity base by allotting 11.70 lakh shares following warrant conversions, which will lead to equity dilution. Despite the profit slump, the company maintains a strong balance sheet with zero debt and no loan defaults.
Key Highlights
Consolidated Net Profit fell 90.3% YoY to ₹22.04 lakhs in Q3 FY26 compared to ₹228.75 lakhs in Q3 FY25.
Consolidated Revenue from Operations grew 9% YoY to ₹1,187.45 lakhs from ₹1,088.87 lakhs.
Standalone Revenue from Operations declined 33.8% YoY to ₹920.99 lakhs.
Equity Share Capital increased from ₹11.80 crore to ₹12.97 crore due to the conversion of 11.70 lakh warrants.
The company remains debt-free with zero financial indebtedness reported as of December 31, 2025.
💼 Action for Investors
Investors should exercise caution as the sharp drop in consolidated margins and net profit indicates operational pressures. The recent equity dilution from warrant conversions further impacts EPS, making the valuation less attractive until profitability recovers.
Apollo Micro Systems Q3 Revenue Surges 70% to ₹252 Cr; Order Book Hits ₹1,305 Cr
Apollo Micro Systems reported its highest-ever quarterly performance with revenue surging 70% YoY to ₹252 crores and 9-month PAT climbing 67% to ₹71 crores. The company maintains a robust consolidated order book of ₹1,305 crores and has provided an aggressive organic growth guidance of 45-50% CAGR for the next three years. Strategically, the firm is transitioning from a subsystem provider to a full-fledged weapon system manufacturer, supported by significant R&D and capacity expansion plans. Management is also actively pursuing acquisitions, with 1-2 deals expected to close before the end of the current financial year.
Key Highlights
Q3 FY26 revenue increased by 70% YoY to ₹252 crores, while 9M FY26 PAT rose 67% to ₹71 crores.
Consolidated order book stands at ₹1,305 crores as of December 31, 2025.
Management projects a 45-50% organic revenue CAGR over the next three years, excluding acquisitions.
Allocated ₹50-60 crores for near-term R&D and ₹100-150 crores for a new 5-acre facility expansion.
Active due diligence underway for three potential acquisitions to enhance technological capabilities.
💼 Action for Investors
Investors should focus on the company's transition into high-value weapon systems and the execution of its ₹1,305 crore order book. The aggressive 45-50% growth guidance and upcoming acquisitions suggest strong momentum, though capital allocation for massive expansions warrants monitoring.
Apollo Micro Systems H1 FY26 PAT Surges 97% to ₹48 Cr; Guides 45-50% CAGR
Apollo Micro Systems reported a robust H1 FY26 with revenue growing 42% semi-annually to ₹359 crores and PAT nearly doubling to ₹48 crores. The company completed the ₹107 crore acquisition of Ideal Explosives Limited, marking a strategic entry into high-energy explosives and weapon filling lines. Management has provided a strong growth guidance of 45-50% CAGR for FY26 and FY27, excluding the impact of the new acquisition. Expansion at Unit 3 is progressing well, with full-fledged production expected by Q1 FY27, potentially increasing capacity by eight times.
Key Highlights
H1 FY26 Revenue grew 42% semi-annually to ₹359 crores with EBITDA margins expanding 600 bps to 28%.
Profit After Tax (PAT) for H1 FY26 rose 97% semi-annually to ₹48 crores.
Completed 100% acquisition of Ideal Explosives Limited for ₹107 crores for backward and forward integration.
Unit 3 Phase 1 partial production has commenced, with an 8x capacity increase expected upon full completion.
Management maintains a revenue growth guidance of 45-50% CAGR for the core business over the next two years.
💼 Action for Investors
Investors should focus on the successful integration of Ideal Explosives and the timely operationalization of Unit 3, which are critical for meeting the high growth guidance. The company's transition from a subsystem provider to a full-fledged weapons manufacturer enhances its long-term valuation in the defense sector.
Apollo Hospitals Q3 FY26: Consolidated PAT Surges 170% YoY to ₹5,023 Million
Apollo Hospitals Enterprise Limited reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's bottom line saw a massive jump, with PAT increasing 170% YoY to ₹5,023 million, driven by strong operational performance across all business verticals. The core Healthcare Services segment maintained healthy EBITDA margins of 24.8%, while the Apollo HealthCo and AHLL segments both recorded 20% revenue growth, signaling strong momentum in digital health and retail clinics.
Key Highlights
Consolidated Revenue increased by 17% YoY to ₹64,774 million in Q3 FY26.
Consolidated PAT witnessed a significant 170% YoY surge, reaching ₹5,023 million.
Healthcare Services (Hospitals) reported an EBITDA margin of 24.8% with 67% occupancy.
Apollo HealthCo (Digital & Pharmacy) revenue grew 20% YoY to ₹28,274 million with 7,113 outlets.
Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, reflecting improved profitability.
💼 Action for Investors
Investors should take note of the significant margin expansion and the massive jump in PAT, which indicates strong operational efficiency. The continued growth in the digital health platform (Apollo 24|7) and the pharmacy network strengthens the company's long-term competitive position.
Apollo Hospitals Q3 FY26 PAT Surges 170% YoY to ₹4,219 Million
Apollo Hospitals reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's Profit After Tax (PAT) saw a massive jump of 170% YoY, reaching ₹4,219 million, driven by strong operational efficiencies and growth across all business segments. Healthcare services remained the primary contributor with a 24.8% EBITDA margin, while the digital health and pharmacy segment (HealthCo) continued its growth trajectory with 20% revenue growth.
Key Highlights
Consolidated PAT increased by 170% YoY to ₹4,219 million in Q3 FY26.
Healthcare Services revenue grew 14% YoY to ₹31,832 million with an EBITDA margin of 24.8%.
Average Revenue per IP Patient (ARPOB) stood at ₹180,917 with 67% occupancy across 10,325 beds.
Apollo HealthCo (Digital & Pharmacy) revenue rose 20% YoY to ₹28,274 million.
Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, showing improved profitability in diagnostics and clinics.
💼 Action for Investors
The strong growth in PAT and steady margins in the core hospital business make this a positive update for long-term investors. Monitor the continued scaling and path to profitability of the Apollo 24|7 digital platform as it integrates further with the pharmacy business.
Apollo Hospitals Q3 FY26: PAT Surges 170% YoY to ₹5,023 Million; HealthCo Turns Profitable
Apollo Hospitals Enterprise Limited reported a robust Q3 FY26 with consolidated revenue growing 15% YoY to ₹64,774 million. The company achieved a significant milestone as its Apollo HealthCo segment (Digital & Pharmacy) turned EBITDA positive at ₹1,279 million, compared to a loss of ₹1,027 million in the previous year. Net profit (PAT) saw a massive 170% jump to ₹5,023 million, driven by strong hospital margins and the digital turnaround. The core Healthcare Services division maintained a healthy 24.8% EBITDA margin with an average revenue per inpatient of ₹180,917.
Key Highlights
Consolidated Revenue increased 15% YoY to ₹64,774 million in Q3 FY26.
Net Profit (PAT) grew by 170% YoY to ₹5,023 million.
Apollo HealthCo achieved EBITDA of ₹1,279 million, a sharp recovery from a ₹1,027 million loss in Q3 FY25.
Healthcare Services (Hospitals) reported 14% revenue growth and 18% EBITDA growth with 67% occupancy.
Pharmacy network expanded to 7,113 outlets with 46 million registered users on the Apollo 24|7 platform.
💼 Action for Investors
The turnaround in the digital health and pharmacy segment is a major positive trigger for the stock's valuation. Investors should maintain a positive outlook given the strong hospital margins and the scaling of the omni-channel healthcare platform.
Apollo Hospitals Subsidiary Acquires Belenus Champion Hospitals for Rs 1,650 Million
Apollo Hospitals' subsidiary, Imperial Hospital and Research Centre Limited, has completed the 100% acquisition of Belenus Champion Hospitals in Bangalore for a total cost of Rs 1,650 million. The target company, which operates a 125-bed facility, reported a turnover of Rs 274.90 million in FY25. Apollo plans to invest a total of Rs 3,000 million to upgrade and expand the facility to 175 beds. The revamped multi-speciality hospital is scheduled to reopen by Q1 FY27, strengthening Apollo's footprint in the Bangalore healthcare market.
Key Highlights
Acquired 100% stake in Belenus Champion Hospitals for a total consideration of Rs 1,650 million including liabilities.
Target company reported FY25 revenue of Rs 274.90 million compared to Rs 305.84 million in FY24.
Total project cost of Rs 3,000 million earmarked for acquisition and expansion to a 175-bed facility.
The hospital is currently being upgraded and is expected to be operational by Q1 FY27.
Acquisition executed through a 90% owned subsidiary, making Belenus a step-down subsidiary of Apollo Hospitals.
💼 Action for Investors
Investors should monitor the progress of the facility upgrade as this acquisition strengthens Apollo's presence in the high-demand Bangalore market. The long-term value will depend on the successful turnaround and scaling of the 175-bed facility by FY27.
Apollo Hospitals Q3FY26 Standalone PAT up 12% YoY to ₹384 Cr; Declares ₹10 Interim Dividend
Apollo Hospitals reported a robust performance for Q3FY26 with standalone revenue growing 15% YoY to ₹2,364 crore. Standalone EBITDA increased by 16% YoY to ₹594 crore, while Profit After Tax rose 12% to ₹384 crore, despite a one-time exceptional charge of ₹11.4 crore related to new labour codes. The Board has declared an interim dividend of ₹10 per share (200% of face value) with a record date of February 16, 2026. The company is also progressing with its strategic restructuring to demerge its pharmacy and digital health businesses.
Key Highlights
Standalone Revenue from operations grew 15% YoY to ₹23,637 million compared to ₹20,548 million in Q3FY25.
Standalone EBITDA rose 16% YoY to ₹5,935 million from ₹5,118 million in the previous year.
Interim dividend of ₹10 per share declared; Record date fixed as February 16, 2026.
Profit After Tax (PAT) increased 12.3% YoY to ₹3,835 million despite an exceptional cost of ₹114 million.
Company has filed an application with NCLT for the demerger of its pharmacy distribution and digital health platform.
💼 Action for Investors
Investors should take note of the steady double-digit growth across key financial metrics and the healthy dividend payout. The upcoming demerger of the pharmacy and digital health business remains a key monitorable for long-term value unlocking.
Apollo Hospitals Declares ₹10 Interim Dividend; Q3 PAT Rises 12% YoY to ₹3,835 Million
Apollo Hospitals has declared an interim dividend of ₹10 per share (200% of face value) for FY26, with the record date fixed for February 16, 2026. The company reported a 15% YoY growth in standalone revenue to ₹23,637 million for the quarter ended December 31, 2025. Standalone Profit After Tax (PAT) grew by 12% YoY to ₹3,835 million, even after accounting for a ₹114 million exceptional charge related to new labour codes. Additionally, the company is progressing with its composite scheme of arrangement for the demerger of its pharmacy and digital health businesses, currently awaiting NCLT approval.
Key Highlights
Interim dividend of ₹10 per share (200% of FV) declared with a record date of February 16, 2026.
Standalone Revenue from operations increased 15% YoY to ₹23,637 million in Q3 FY26.
EBITDA grew 16% YoY to ₹5,935 million, maintaining healthy operational margins.
Net Profit (PAT) for the quarter stood at ₹3,835 million compared to ₹3,416 million in the previous year.
Exceptional item of ₹114 million recorded due to regulatory changes in Labour Codes affecting employee benefits.
💼 Action for Investors
Investors seeking dividend income should ensure they hold the stock before the February 16 record date. Long-term investors should track the NCLT approval process for the pharmacy business demerger as it could unlock significant value.
Apollo Hospitals Q3 PAT Rises 12% to ₹383.5 Cr; Declares ₹10 Interim Dividend
Apollo Hospitals Enterprise Limited reported a steady performance for Q3 FY26, with standalone revenue from operations growing 15% YoY to ₹2,363.7 crore. Net profit increased by 12.3% YoY to ₹383.5 crore, despite a one-time exceptional charge of ₹11.4 crore due to new labour code provisions. The company rewarded shareholders with an interim dividend of ₹10 per share. Furthermore, the company has moved forward with its restructuring plan, filing an application with the NCLT for the demerger of its pharmacy and digital health businesses.
Key Highlights
Standalone Revenue from operations increased 15% YoY to ₹2,363.7 crore from ₹2,054.8 crore.
EBITDA grew by 16% YoY to ₹593.5 crore compared to ₹511.8 crore in the same quarter last year.
Profit After Tax (PAT) stood at ₹383.5 crore, up from ₹341.6 crore in Q3 FY25.
Declared an interim dividend of ₹10 per share (200% of face value) with a record date of Feb 16, 2026.
Exceptional item of ₹11.4 crore recognized due to increased gratuity and leave liabilities under new Labour Codes.
💼 Action for Investors
Investors should maintain a positive outlook given the consistent growth in the core healthcare segment and the upcoming value unlocking from the pharmacy business demerger. The interim dividend provides an immediate yield benefit while waiting for the restructuring to conclude.
Apollo Tyres Q3 FY26: Record Revenue of ₹77.4B and ₹5,800 Cr Capex Plan Announced
Apollo Tyres reported its highest-ever quarterly consolidated revenue of INR 77.4 billion, marking a 12% YoY growth driven by robust double-digit volume growth in India. The company achieved significant deleveraging, with net debt falling to INR 13 billion from INR 26 billion in the previous quarter, resulting in a Net Debt/EBITDA of 0.4x. A major expansion plan of INR 5,800 crore was approved for the Andhra Pradesh plant to be spent over FY27-29 to address high capacity utilization. While India margins were slightly impacted by BCCI sponsorship costs, European margins remained resilient at 17.9%.
Key Highlights
Consolidated revenue reached a record INR 77.4 billion, up 12% YoY with consolidated EBITDA margins at 15.3%.
Net debt reduced by 50% in one quarter to INR 13 billion, driven by strong operational cash flows.
Approved INR 5,800 crore capex for AP plant expansion (PCR and TBR) to be executed over the next three financial years.
India volume growth was in mid-teens for OEM and replacement segments, while exports grew nearly 20%.
European operations saw premiumization gains with the Ultra High Performance (UHP) mix rising to 52%.
💼 Action for Investors
Investors should focus on the company's aggressive debt reduction and the start of a new growth capex cycle which signals management's confidence in long-term demand. The temporary margin pressure from branding spends is expected to normalize by FY27, making this a strong pick for long-term growth.
Apollo Micro Systems Reports Zero Deviation in Utilization of Rs 185.13 Cr Fundraise
Apollo Micro Systems has confirmed zero deviation in the utilization of proceeds from its preferential issue for the quarter ended December 31, 2025. During the quarter, the company received Rs 185.13 crore, representing 75% of the warrant application money for 2.16 crore share warrants. These funds remained unutilized as of the quarter-end due to pending listing approvals from the stock exchanges. The total estimated proceeds from the preferential issue have been revised to Rs 742.25 crore, with major allocations toward working capital and R&D.
Key Highlights
Confirmed zero deviation or variation in the use of funds raised via preferential issue.
Received Rs 185.13 crore during Q3 FY26 as 75% warrant application money for 2,16,52,792 warrants.
Total issue proceeds revised to Rs 74,225 Lakhs (Rs 742.25 Cr) from an original estimate of Rs 81,608 Lakhs.
Rs 185.13 crore remains unutilized as of Dec 31, 2025, pending listing approvals from BSE and NSE.
Primary fund allocation includes Rs 454.77 Cr for working capital and Rs 68.21 Cr for R&D expenditure.
💼 Action for Investors
Investors should track the deployment of the unutilized Rs 185.13 crore once listing approvals are secured, as it will support the company's working capital and R&D initiatives. The lack of deviation indicates disciplined capital management by the board.
Apollo Micro Systems Reports Record Q3 FY26 Revenue and Expansion into Defence Explosives
Apollo Micro Systems delivered its highest-ever quarterly and nine-month revenue for the period ending December 31, 2025. The company is successfully transitioning from a subsystem provider to a complete weapon systems manufacturer, indigenizing critical technologies like underwater mines and torpedo homing systems. A major strategic milestone includes securing licenses for manufacturing high-energy explosives (HMX and TNT) with capacities of 50 MTPA and 500 MTPA respectively. Furthermore, the company is advancing into Directed Energy Weapons (DEW) and Unmanned Aerial Systems, significantly broadening its addressable market within the Indian defence sector.
Key Highlights
Achieved highest ever revenue for both Q3 FY26 and the 9-month period ending December 2025
Secured manufacturing licenses for 50 MTPA of HMX and 500 MTPA of TNT explosives valid for 15 years
Company accounts for approximately 60% of electronics and mechanical systems in indigenized missile programs
Only Indian company offering a complete range of Shallow Water, Deep Water, and Limpet Under Water Mines
Trials for Vehicle Mounted Counter Drone Systems (VMCSDS) scheduled to initiate in Q1 FY27
💼 Action for Investors
Investors should consider the company's transition to high-value complete weapon systems and its entry into the explosives market as strong catalysts for margin expansion. Monitor the progress of the Unit-III facility and the upcoming trials for counter-drone systems in early FY27.
Apollo Micro Systems Q3 Revenue Surges 70% YoY to ₹252 Cr; PAT Up 25%
Apollo Micro Systems reported its highest-ever quarterly revenue of ₹252.2 crore for Q3FY26, representing a significant 70% YoY growth. The 9-month performance was equally strong, with PAT rising 67% YoY to ₹70.6 crore and EBITDA margins expanding by 134 bps. Management has provided a robust growth guidance of 45-50% CAGR over the next three years, backed by a healthy order book of ₹1,305 crore. However, investors should note that EPS growth was tempered by equity dilution from preference share issuances.
Key Highlights
Q3FY26 Revenue surged 70% YoY to ₹252.2 crore, driven by robust order book execution.
9MFY26 PAT grew 67% YoY to ₹70.6 crore with a solid order book standing at ₹1,305 crore.
Management projects a 45-50% CAGR for the core business over the next three years.
EBITDA for Q3 rose 33% YoY to ₹50.4 crore, though Q3 margins (20%) were lower than Q2 (26.3%).
An additional acquisition by subsidiary ADIPL is expected to be completed by the end of FY26.
💼 Action for Investors
The strong revenue growth and aggressive multi-year guidance make this a positive update for long-term investors in the defense electronics sector. Monitor the impact of equity dilution on EPS and the integration of upcoming acquisitions.
Apollo Micro Systems Q3 Revenue Surges 70% YoY to ₹252.2 Cr; Guides 45-50% CAGR
Apollo Micro Systems reported its highest-ever quarterly performance for Q3FY26, with revenue surging 70% YoY to ₹252.2 crore. The company's 9-month PAT grew by 67% YoY to ₹70.6 crore, supported by a robust order book of ₹1,305 crore. Management has provided a strong growth outlook, guiding for a 45-50% revenue CAGR over the next three years. Additionally, the company announced an upcoming acquisition by its subsidiary ADIPL, expected to conclude by the end of FY26.
Key Highlights
Q3FY26 Revenue from operations grew 70% YoY to ₹2,522.2 million.
9MFY26 Profit After Tax (PAT) increased by 67% YoY to ₹705.9 million.
Order book remains strong at ₹13,050 million as of February 2026.
Management guided for a 45-50% revenue CAGR over the next three years for the core business.
EBITDA margins for 9MFY26 expanded by 134 basis points YoY to 24.6%.
💼 Action for Investors
The stock remains a strong growth play in the defense electronics sector given the 45-50% CAGR guidance and healthy order book. Investors should monitor the impact of equity dilution on EPS and the details of the upcoming ADIPL acquisition.
Apollo Micro Systems Q3 Revenue Surges 70% YoY to ₹252 Cr; 9M PAT Grows 67%
Apollo Micro Systems reported its highest-ever quarterly revenue of ₹252.2 crore in Q3FY26, a 70% YoY increase driven by robust order execution. For the nine-month period (9MFY26), PAT surged 67% YoY to ₹70.6 crore, supported by a 134 bps expansion in EBITDA margins. The company maintains a strong order book of ₹1,305 crore and has provided an aggressive growth guidance of 45-50% CAGR for the next three years. Additionally, a new acquisition via its subsidiary ADIPL is expected to be finalized by the end of the current financial year.
Key Highlights
Q3FY26 Revenue from operations grew 70% YoY to ₹2,522 million.
9MFY26 PAT increased by 67% YoY to ₹706 million with EBITDA margins at 24.6%.
Current order book stands at a robust ₹13,050 million (₹1,305 crore).
Management projects a revenue CAGR of 45-50% over the next three years for the core business.
Upcoming acquisition by subsidiary ADIPL to be completed by the end of FY26.
💼 Action for Investors
The strong revenue momentum and high growth guidance make this a positive update for long-term investors in the defense electronics space. However, investors should monitor the impact of equity dilution from preference shares on EPS despite the strong bottom-line growth.